| 1 |
34932238 | Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease. | 2022 Feb |
1 |
| 2 |
34007159 | An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis. | 2021 |
2 |
| 3 |
32570252 | Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More. | 2020 |
1 |
| 4 |
32810927 | A label-free impedance assay in endothelial cells differentiates the activation and desensitization properties of clinical S1P1 agonists. | 2020 Oct |
1 |
| 5 |
33658933 | Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | 2020 |
1 |
| 6 |
31317509 | Innovations in Oral Therapies for Inflammatory Bowel Disease. | 2019 Aug |
1 |
| 7 |
26990079 | Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity. | 2016 Jun |
2 |